ATTO (Attovia Therapeutics) Debt-to-Asset : 0.03 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATTO Attovia Therapeutics Inc ATTO
8 GF Score
Price $20.70
View Full Analysis

What is Attovia Therapeutics Debt-to-Asset?

Attovia Therapeutics ATTO -6.94% 8 Debt-to-Asset is 0.03 as of Mar. 2026. GuruFocus rates ATTO with a GF Score™ of 8/100.

Attovia Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $1.98 Mil. Attovia Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $2.83 Mil. Attovia Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2026 was $146.09 Mil. Attovia Therapeutics's debt to asset for the quarter that ended in Mar. 2026 was 0.03.

Attovia Therapeutics  (NAS:ATTO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Attovia Therapeutics Debt-to-Asset Related Terms

Attovia Therapeutics Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Attovia Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Attovia Therapeutics Debt-to-Asset Chart

Attovia Therapeutics Annual Data
Trend Dec24 Dec25
Debt-to-Asset
0.00 0.03

Attovia Therapeutics Quarterly Data
Dec24 Mar25 Dec25 Mar26
Debt-to-Asset 0.00 0.00 0.03 0.03

ATTO vs : Debt-to-Asset Comparison

For the Biotechnology subindustry, Attovia Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Attovia Therapeutics Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Attovia Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Attovia Therapeutics's Debt-to-Asset falls into.


ATTO
8GF Score
Attovia Therapeutics Inc ATTO
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Attovia Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Attovia Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.921 + 3.341) / 165.893
=0.03

Attovia Therapeutics's Debt-to-Asset for the quarter that ended in Mar. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.978 + 2.826) / 146.086
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.03 mean?
Attovia Therapeutics (ATTO) has a Debt-to-Asset of 0.03 as of Mar. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Attovia Therapeutics and its competitors.
Is Attovia Therapeutics' Debt-to-Asset too high?
Attovia Therapeutics' current Debt-to-Asset is 0.03. Overall, Attovia Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Attovia Therapeutics' Debt-to-Asset compare to ?
Attovia Therapeutics' Debt-to-Asset of 0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Attovia Therapeutics and its competitors. Attovia Therapeutics's current Debt-to-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Attovia Therapeutics stock overvalued right now?
Attovia Therapeutics (ATTO) has a current Debt-to-Asset of 0.03. The current Debt-to-Asset is 0.03. Attovia Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Attovia Therapeutics (ATTO), the current Debt-to-Asset is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Attovia Therapeutics Business Description

Comparable Companies
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
8GF Score

Get the complete analysis for ATTO

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.70
Price